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Here we describe the expression and function of a HIF-1-regulated protein pyruvate dehydrogenase kinase-1 (PDK-1) in head and
neck squamous cancer (HNSCC). Using RNAi to downregulate hypoxia-inducible PDK-1, we found that lactate and pyruvate
excretion after 16–48h of hypoxia was suppressed to normoxic levels. This indicates that PDK-1 plays an important role in
maintaining glycolysis. Knockdown had no effect on proliferation or survival under hypoxia. The immunohistochemical expression of
PDK-1 was assessed in 140 cases of HNSCC. PDK-1 expression was not expressed in normal tissues but was upregulated in HNSCC
and found to be predominantly cytoplasmic with occasional strong focal nuclear expression. It was strongly related to poor outcome
(P¼0.005 split by median). These results indicate that HIF regulation of PDK-1 has a key role in maintaining lactate production in
human cancer and that the investigation of PDK-1 inhibitors should be investigated for antitumour effects.
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The upregulation of glycolysis is a well-recognised phenotype of
cancer and it is regulated by hypoxia-inducible factor (HIF) in
hypoxic conditions. Hypoxia-inducible factor is a heterodimeric
transcription factor, consisting of a and b subunits, which directs a
broad range of responses in hypoxic cells (Maxwell et al, 1997).
Both proteins are members of the basic helix–loop–helix super-
family of transcription factors (Wang et al, 1995). In the presence
of oxygen, two prolyl sites within a central domain of HIF-1a are
hydroxylated by prolyl hydroxylase enzymes, which leads to HIF-
1a degradation through the von Hippel-Lindau E3 ubiquitin ligase
complex and the 26S proteasome (Maxwell et al, 2001). Upon
activation, the HIF-1 complex binds to target genes at sites
containing the core recognition sequence 50-RCGTG-30, also
known as the hypoxia regulatory element (Minchenko et al,
1994), which leads to the upregulation of genes involved in
angiogenesis (VEGF), glucose transport (GLUT-1), glycolytic
enzymes (Hexokinase 2) and pH regulation (CA9).
Under hypoxic conditions, anaerobic glycolysis is maintained by
conversion of pyruvate to lactate, a reaction catalysed by lactate
dehydrogenase A (Koukourakis et al, 2005a). In cancer cells,
pyruvate is transformed into lactate regardless of the presence of
oxygen, a process called the Warburg effect (Warburg, 1956). This
results in an increased glycolytic rate and shift to lactate
production in cancer cells.
A key branch point in the glycolytic pathway is the production
of pyruvate, which in anaerobic conditions is metabolised to
lactate and in normoxia by pyruvate dehydrogenase (PDH) to
acetyl-CoA, the first step in the TCA cycle (Yeaman, 1989; Reed,
2001; Harris et al, 2002; Fries et al, 2003; Sugden and Holness,
2003). PDH activity is controlled by two regulatory enzymes;
pyruvate dehydrogenase kinase (PDK), which phosphorylates and
inactivates the enzyme and pyruvate dehydrogenase phosphatase,
which dephosphorylates the enzyme to the active form (Kristo
et al, 2004; Martin et al, 2005). Four PDK isoenzymes have been
identified in humans and they exhibit tissue-specific expression
(Popov et al, 1997; Bowker-Kinley and Popov, 1999). Pyruvate
dehydrogenase kinase-1 has been detected in the heart (Wu et al,
1998; Bowker-Kinley and Popov, 1999; Sugden et al, 2000), the
pancreatic islets (Sugden et al, 2001), the liver, and the skeletal
muscle (Peters et al, 2001). Conversion of pyruvate to acetyl CoA
by PDH is vital in providing a link between glycolysis and the
Krebs cycle, and aerobic respiration, and as a donor for fatty acid,
ketone body and cholesterol synthesis.
As the human squamous head and neck cancer (HNSCC) is
among the most hypoxic of tumours and because there is evidence
of substantial differences between cell lines in the hypoxia
transcriptome (Kelly et al, 2003; Chi et al, 2006), we investigated
head and neck cancer cell lines to evaluate if there were any genes
not previously reported to be hypoxia inducible, aiming then to
evaluate function and clinical significance.
Recently, two reports have identified PDK-1 as a hypoxia-
responsive protein that regulates the function of the mitochondria
under hypoxic conditions by reducing pyruvate conversion to
acetyl CoA, resulting in a drop in mitochondrial oxygen
consumption resulting in and preventing the accumulation of
reactive oxygen species (Kim et al, 2006; Papandreou et al, 2006).
In this study, we provide further evidence that PDK-1 is
upregulated in hypoxia and that it is under the control of the HIF-1
Received 10 January 2008; revised 12 March 2008; accepted 12 March
2008; published online 10 June 2008
*Correspondence: Professor AL Harris;
E-mail: aharris.lab@imm.ox.ac.uk
4These authors contributed equally to this work.
British Journal of Cancer (2008) 98, 1975–1984
& 2008 Cancer Research UK All rights reserved 0007– 0920/08 $30.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
stranscription factor in HNSCC cell lines and many other cancer
cell types. We show that PDK-1 contributes substantially to
maintaining increased levels of lactate, rather than protecting
against free radicals produced under hypoxic conditions from
mitochondria. Upregulation of this pathway in head and neck
cancer is associated with poor outcome and an aggressive
phenotype. Expression of this pathway in vivo may help cancer
cell survival by maintaining lactate levels and therefore warrants
further investigation.
MATERIALS AND METHODS
Cell culture
Human colon cell lines CAKI-1, L5174T and SW620 and breast cell
line MDA-MB-231 were grown in DMEM. Human HNSCC cell lines
TR-138, SCC-4 and SCC-25 were cultured in HAMS F12, DMEM
plus 0.4mgml
 1 hydrocortisone and DMEM and HAMS F12 in 1:1
plus 0.4mgml
 1 hydrocortisone, respectively. Human renal cell
lines RCC4vhl and RCC4ev were grown in a-MEM plus 10mgml
 1
G418. All cell culture medium were supplemented with 10% fetal
bovine serum, penicillin (50IUml
 1) and streptomycin sulphate
(50mgml
 1). Hypoxic exposure (0.1% O2,5 %C O 2) was performed
in a Heto-Holten CellHouse 170 incubator (RS Biotech, Irvine,
Scotland). A humidified gas-sorted anoxic incubator-gloved box
(InVivo2 400; Ruskin, Leeds, UK) was used for anoxic experi-
ments. The gas was sorted using a Ruskin Microaerophilic gas
sorter, resulting in 5% H2,5 %C O 2, and 90% N2. Two previously
unused palladium catalysts were used to scavenge traces of oxygen.
Cell lines were obtained from Cancer Research UK.
Gene silencing by RNA interference
The target sequences for HIF-1, HIF-2 and scramble control RNAi
were selected from the relevant ORF region of the human cDNA
sequence according to the manufacturer’s recommendations
(Cruachem Limited, Glasgow, UK) and submitted to a Basic Local
Alignment Search Tool search (National Centre for Biotechnology
Information database) to ensure targeting of a single gene. Details
of the oligonucleotides (which were purchased from Eurogentec,
Southampton, UK) were as follows: HIF-1 antisense, 50-CUGAUGA
CCAGCAACUUGAdTdT-30; HIF-1 sense, 50-UCAAGUUGCUGGUC
AUCAGdTdT-30; HIF-2 antisense, 50-CAGCAUCUUUGAUAGCAG
UdTdT-30; HIF-2 sense, 50ACUGCUAUCAAAGAUGCUGdTdT-30;
control antisense, 50-ACGACACGCAGGUCGUCAUdTdT-30; and
control sense, 50-AUGACGACCUGCGUGUCGUdTdT-30 were
synthesised and annealed to form duplexes. The resulting duplexes
were transfected at 25nM into TR-138 cells using oligofectamine
reagent (Invitrogen, Paisley, UK) in serum-free Optimem (Invitro-
gen) for 4h. The cells were allowed to recover overnight in
medium with serum before further treatments.
The target sequence for PDK-1 was selected from the ORF region
of the human PDK-1 cDNA sequence using Dharmacon siDESIGN
Center guidelines and criteria developed by Dharmacon scientists
and described by Reynolds et al (2004) and submitted to a Basic
Local Alignment Search Tool search (National Centre for
Biotechnology Information database) to ensure targeting of a
single gene. Two oligonucleotides consisting of ribonucleosides
with 20-deoxyribonucleosides (dTdT) at the 30 ends, 50-AGUCGCA
UUUCAAUUAGAAdTdT-30 and 50-UUCUAAUUGAAAUGCGACU
dTdT-30, were synthesised and annealed to form duplexes. The
resulting duplexes were transfected at 20nM as described above.
Microarray analysis: preparation and labelling of RNA and
analysis
HG-U133A Affymetrix GeneChips
s were used to profile the
HNSCC, SCC-25. The HG-U133A GeneChip consists of 22283
elements representing 11870 unique ensemble gene identifiers.
SCC-25 cells were transfected with HIF-1, scramble and mock
RNAi, and exposed to normoxia and hypoxia for 16h. Total RNA
was extracted using TRI Reagent (Sigma, Poole, UK) followed by
reverse transcription using High Capacity cDNA Archive Kit
(Applied Biosystems, Warrington, UK). First- and second-strand
cDNA synthesis was performed using Superscript ds-cDNA
Synthesis Kit (Invitrogen) and 10mg of total RNA. Clean-up of
double-stranded cDNA was carried out using Phase Lock Gels, 2ml
light (Eppendorf, Cambridge, UK), followed by synthesis of
labelled cRNA with the BioArray High Yield RNA Transcript
Labelling Kit (ENZO, Affymetrix). Purification of cRNA and
quantification was done with RNeasy Mini Kit (Qiagen, Crawley,
UK), and this was followed by cRNA fragmentation using 30mg
cRNA and fragmentation buffer (200mM Tris-acetate pH 8.1,
500mM MKOAc, 150mM MgOAc). Hybridisation cocktail for
human HG-U133A array utilised the Gene Chip Eukaryotic
Hybridisation Control Kit (ENZO, Affymetrix), and hybridisation,
washing, staining, and scanning of the chip was performed
according to the manufacturer’s instructions. Data were labelled
as MIAME compliant. Raw signal files were background-corrected
and normalised using the gcrma modification of the rma normal-
isation procedure (Irizarry et al, 2003) available from the
Bioconductor project (www.bioconductor.org) for the R statistical
language. Log2 ratios of hypoxia signal to control signal were
generated for each probeset. A list was generated that contained
those probesets for which an average absolute fold change of at
least 1.5 was observed between normoxic and hypoxic genes, also
in addition to a subset of those regulated by HIF-1 and HIF-2.
Where a gene was represented by more than one probeset the
average signal value was used. This list was used to generate a list
of statistically significant (Pp0.01) probesets with the eBayes
approach as implemented in the limma package of the BioCon-
ductor, which was annotated with regard to gene function and the
biological processes present using the gene ontology database
(Irizarry et al, 2003). An analysis for the statistically significant
enrichment of gene ontology terms in this list was carried out to
identify functional themes represented.
Visualisation of this gene list was performed using the
hierarchical clustering algorithm with euclidean distance and
single linkage. The gene list was annotated for gene ontology terms
using the GO database and analysis for statistically significant
enrichment of terms was performed.
Immunostaining
Paraffin-embedded tissue samples from 140 consecutive cases of
squamous cell head and neck cancer from the ENT department,
Radcliffe Infirmary, Oxford, were retrieved and representative
tumour areas were mounted on multitissue array slides. Additional
tissue sections from apparently normal tongue, buccal mucosa and
tonsils were also retrieved for immunohistochemistry. The work
was carried out after approval from the Oxford Ethics Committee.
All patients were treated with curative intent with primary surgery.
The decision regarding postoperative RT was made in a multi-
disciplinary setting following surgery in conjunction with the
histology results. In all 87% (122 of 140) of patients received
postoperative RT. Patients and disease characteristics are shown in
Table 2.
A modified streptavidin technique was used for immuno-
histochemistry as previously reported (Koukourakis et al, 2006).
Sections were deparaffinised and peroxidase was quenched with
methanol and H2O2 3% for 15min. Microwaving for antigen
retrieval was used (3 5min). The primary anti-POK-1 antibody
(KAP-PK112, Bioquote Limited, York, UK) was applied overnight
at a concentration of 10mgml
 1. Following washing with TBS,
sections were incubated with a secondary antibody (Kwik Kit, Cat.
No. 404050, Thermo Shandon, Pittsburgh, PA 15275, USA) for
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was applied for 15min and sections were again washed in TBS. The
colour was developed by 15min incubation with DAB solution and
sections were weakly counterstained with haematoxylin.
Statistical analysis was performed using the GraphPad Prism 4.0
and the Instat 3.1 package (GraphPad Software Inc., USA). A
Fisher’s exact test was used for testing relationships between
categorical variables (contingency tables) as appropriate. The
Kaplan–Meier survival curves were used to assess the impact of
various variables in the disease-specific survival of patients. A Cox
proportional hazard model was used to assess the effect of assessed
parameters on death events. A P-value of o0.05 was used for
significance.
Western blotting
Whole cell extracts were made by homogenising cells in lysis
buffer (6.2M urea, 10% glycerol, 5mM DTT, and 1% SDS plus
protease inhibitors). Whole cell extract was separated on 10% SDS-
PAGE and transferred to polyvinylidene difluoride membrane.
Primary antibodies used were mouse anti-HIF-1a, rabbit anti-HIF-
2a (BD Transduction Laboratories, Lexington, KY, USA), goat
anti-PDK-1 (Stressgen, Cambridge, UK) and PDH (IgG2a mono-
clonal antibody against E2/E3bp and E2 subunits of mitochondrial
PDH, Molecular Probes Inc., Eugene, OR, USA), and mouse anti-
b-tubulin monoclonal antibody (Sigma, Poole, UK). Immuno-
reactivity was visualised with horseradish peroxidase-linked goat
anti-mouse, anti-rabbit serum or rabbit anti-goat (Dako, Ely, UK)
at 1:1000 and detected with enhanced chemiluminescence
(Amersham, Little Chalfont, UK).
RNA extraction and reverse transcription
Cells were rinsed with PBS and drained thoroughly. RNA was
extracted from the cells using Tri reagent (Sigma, Poole, UK). The
quantity and quality of RNA extracted were assessed using
NanoDrop ND 1000 Spectrophotometer (NanoDrop Technologies)
and the Agilent 2100 Bio-analyzer (Agilent Technologies, West
Lothian, UK), respectively. RNA samples were stored at –801C.
cDNA was synthesized by reverse transcribing RNA using the High
Capacity cDNA Archive Kit (Applied Biosystems, Warrington, UK)
following the manufacturer’s instruction.
Real-time quantitative PCR
Real-time quantitative PCR (qPCR) reactions were performed in
triplicate using the Corbett Research Rotor Gene RG-3000 (Sydney,
Australia). Each reaction was performed in an individual tube and
made up to 25ml containing 10ml cDNA, 12.5mlT a q M a nP C R
Master Mix (Abgene, Epsom, UK), 0.25mlp r o b e ,1ml of forward and
reverse primer and 0.2mlH 2O. Conditions for the PCR reaction were
2min at 501C, 10min at 951C and then 40 cycles, each consisting of
15s at 951C, and 1min at 601C. b-Actin was used as a reference gene
using primers (Invitrogen) 50-CCCAGCACAATGAAGATCAA-30
forward and 50-CGATCCACACGGAGTACTTG-30 reverse with probe
63 (Roche, Lewes, UK). Primers against PDK-1 50-CTGGGTAATGA
GGATTTGACTGT-30 forward and 50-AAGTCTGTCAATTTTCCTCA
AAGG-30 reverse with probe 10 were used for qPCR. Relative
quantitation of gene expression was performed using the method
described by Pfaffl (Pfaffl, 2001). In brief, comparisons were made
between the number of cycles required for the fluorescence of a
sample to reach a predetermined threshold that lay within the
exponential phase and above the non-specific background. The
relative ratio of gene expression was calculated as follows:
Relativeratio ¼
ðEtargetÞ
DCtTARGETðmeancomparator meansampleÞ
ðErefÞ
DCtREFðmeancomparator meansampleÞ
Etarget¼reaction efficiency of the gene of interest, Eref¼reaction
efficiency of the reference gene, DCt¼the cycle difference between
the comparator and the sample. All calculations are based on the
mean value of PCRs performed in triplicate.
Measurement of mitochondrial dehydrogenase activity in
intact cells
Cells were seeded at 2.5–10 10
3cells per well 100ml in 96-well
plates 24h prior to experimental treatment in triplicate and
incubated in hypoxia or normoxia for 16, 24 and 48h. Cell viability
was measured by measuring metabolic conversion of the dye MTS
Cell Titer 96
s AQueous One Solution Cell Proliferation Assay
(Promega, Southampton, UK). In each well of a 96-well plate, 20ml
of MTS was added and plates were incubated for 2–4h in a cell
culture incubator. MTS assay results were read in a 96-well format
plate reader by measuring absorbance at 490nm.
Growth curves
TR-138 cells were transfected with siRNA as previously described.
After recovery overnight in HAMS F12 with serum, the transfected
cells were reseeded in triplicate at 100000 cells per well of a 6-well
plate. The cells were grown for 16, 24, 48 and 72h in normoxia and
hypoxia (0.1% oxygen). The cells were counted using a coulter
counter (Beckman, High Wycombe, UK). The media was retained
to measure lactate/pyruvate concentrations and stored at  201C.
Lactate/pyruvate assay
The lactate and pyruvate concentrations were measured from the
media collected from the growth curve experiments, according to the
manufacturer’s instructions (Instruchemie, Zwet, The Netherlands).
RESULTS
Microarray analysis of hypoxia-induced genes
SCC-25 cells were cultured and transfected with the relevant RNAi. All
experiments were conducted with HIF-1a,H I F - 2 a,s c r a m b l ea n d
mock RNAi transfection, performed simultaneously and exposed to
Table 1 Hypoxia upregulated genes. Fold change relative to normoxic
expression
Fold change Gene description
7.2 Enolase 2 (g, neuronal)
6.7 Egl nine homologue 3 (C. elegans)
6.3 Angiopoietin-like 4
6.2 BCL2/adenovirus E18 19kDa interacting protein 3
6.2 NADH-ubiquitone oxidoreductase MLRQ subunit binding
5.3 Carbonic anhydrase IX
5.3 Lysyl oxidase
4.3 Protein phosphatase 1, regulatory, (inhibitor) subunit 3C
4.2 DNA damage-inducible transcript 4
4.2 Solute carrier family 6 (neurotransmitter transporter, creatine)
3.8 Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2
3.6 MAX interactor 1
3.4 Cyclin G2
3.2 Jumonji domain containing 1A
3.3 Solute carrier family 2 (facilitated glucose transporter), 1
3.1 Aldolase C
3.1 Phosphoglycerate kinase 1
3.0 Adrenomedulin
2.6 Ephrin A1
2.6 Protein tyrosine phosphatase, receptor type R
2.3 Mucin 1, transmembrane
2.1 Carbonic anhydrase X11
1.8 Pyruvate dehydrogenase kinase 1
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25 cells in triplicate. Three separate experiments were performed to
minimise the biological variability (Zien et al, 2003). The RNA quality
was assessed using the Agilent bioanalyser before being converted
into labelled cDNA and hybridised to the gene array chip.
The results from the three replicates for each condition were
pooled together for the analysis. A total of 392 genes were identified
that were upregulated in hypoxia. Of those genes, a number were
identified that are regulated by hypoxia and the HIF-1a transcrip-
tion factor, including BCL2, carbonic anhydrase IX and adreno-
medullin. Several genes not previously described at the time as
being regulated by hypoxia were also identified, including PDK-1
(Table 1).
Expression of PDK-1 in different tumour cell lines
To assess whether PDK-1 was specific to HNSCC, the RNA and
protein expression of PDK-1 and PDH was quantified in a series of
HNSCC cells, colon cancer cells, breast cancer cells, and renal
cancer cells (Figure 1).
In three HNSCC cell lines (SCC-4, SCC-25, TR-138) and two
colon cancer cell lines (SW620, LS174T), there were similar
findings. PDK-1 mRNA and protein expression was increased
in hypoxia, but there was no increase in PDH. Of the three
breast cancer cell lines, two (MDA-231 and MCF-7) demonstrated
an increase in PDK-1 mRNA and protein expression in
hypoxia. The third one (T47D) did not demonstrate an increase
in mRNA or protein expression of PDK-1 or PDH. In the three
renal cancer cell lines tested, RCC4-wt vHL demonstrated an
increase in mRNA and protein expression of PDK-1. RCC4-ev,
which constitutively express HIF-1a, did not demonstrate any
hypoxic upregulation of PDK-1 mRNA. CAKI-1 cells demonstrated
an increase in mRNA and protein PDK-1 expression. These
findings indicate widespread upregulation of PDK-1 but not PDH
in response to hypoxia.
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Figure 1 mRNA and protein expression of PDK-1 and PDH in (A) head and neck cancer cells, (B) colon cancer cells, (C) breast cancer cells and (D)
renal cancer cells. *Po0.05 between hypoxia and normoxia.
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sRegulation of PDK-1 by HIF-1
The cell line TR-138 was used for gene silencing experiments.
These were conducted with HIF-1a, HIF-2a, scramble and mock
transfection, performed simultaneously and exposed to 16h
hypoxia (0.1% pO2) or normoxia. Selective gene silencing was
confirmed by Q-PCR and western blot analysis (Figure 2A and B).
Q-PCR was performed in triplicate and the experiment repeated on
three separate occasions such that each data point represents
multiple recordings and the s.e. is displayed. All calculations were
performed using the mathematical model described by Pfaffl
(Pfaffl, 2001).
PDK-1 RNA was significantly (Po0.05) upregulated in hypoxia,
and HIF-1a RNAi produced a significant (Po0.05) reduction in
PDK-1 mRNA expression. The mRNA expression of PDK-1 was
unaffected in cells treated with HIF-2a RNAi (Figure 2A). PDK-1
protein was also suppressed after HIF-1 RNAi treatment
(Figure 2B).
Effect of PDK-1 knockdown on total cellular
dehydrogenase activity
The CellTiter 96 non-radioactive cell proliferation assay was used
to measure dehydrogenase enzyme activity. Mainly extra mito-
chondrial dehydrogenases are measured in this assay, and PDH is
one of these (Berridge and Tan, 1993; Dunigan et al, 1995). Hence,
we used this assay as a measure in intact cells of the overall effect
of inhibiting PDK-1 using RNAi. PDK-1 gene expression could be
silenced using RNAi for over 72h (Figure 3A). Treatment of TR-
138 cells with PDK-1 RNAi resulted in 3–4 fold higher
dehydrogenase activity both in normoxia and hypoxia (Figure 3B).
Effect of PDK-1 knockdown on growth rate in hypoxia
A cell growth assay was used as an initial method of assessing
function. Cells were transfected with PDK-1 RNAi before being
seeded at a concentration of 100000cells in a 6-well plate in
triplicate. The cells were then exposed to 16, 24, 48 and 72h of
hypoxia before being counted. Each experiment was repeated three
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Figure 2 (A) mRNA and (B) protein expression of PDK-1 in TR-138
cells in normoxia and hypoxia having been treated with scramble (scr), HIF-
1a RNAi (HIF1-) and HIF-2a RNAi (HIF2-) siRNA. * indicates Po0.05
between scramble normoxia and hypoxia. ** indicates Po0.05 between
RNAi-treated cells and scramble-treated cells in hypoxia.
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Figure 3 (A) RNAi time course for inhibition of PDK-1 (p) expression
and scramble siRNA control (s) on PDK-1 expression (B) Measurement of
PDH activity using CellTiter 96 non-radioactive cell proliferation assay TR-
138 cells treated with PDK-1 and scramble (sc) RNAi after 16, 24 and 48
normoxia and hypoxia. (C) Cell growth of TR-138 cells treated with PDK-1
RNAi after 16, 24, 48 and 72h in normoxia and hypoxia, (D) Re-
oxygenation after 48h anoxia. Mean and s.e. of three experiments, each
performed in triplicate.
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stimes (Figure 3C). Although there was a general reduction in
growth when cells were exposed to hypoxia, there was
no significant difference in growth between cells transfected
with PDK-1 RNAi and scramble transfection in normoxia or
hypoxia.
Effect of PDK-1 knockdown on growth after reoxygenation
after 48h of anoxia
After 48h of exposure to anoxia, TR-138 cells treated with PDK-1
and scramble RNAi were reoxygenated for 48h in an incubator
with normal 21% O2 (normoxia). During anoxia, there was no
significant difference between the growth of scramble or PDK-1
transfected cells. After reoxygenation, there was no significant
difference in growth until a minor difference at 48h reoxygenation
(P¼0.04) (Figure 3D).
Effect of PDK-1 knockdown on lactate production
The concentration of excreted pyruvate and lactate was measured
in the culture media from the cell growth experiments and was
corrected for the final cell count number. Each experiment,
performed in triplicate, was repeated three times (Figure 4A–C).
After 16h, there was a significant increase in the excreted lactate
concentration between cells exposed to normoxia and hypoxia
and treated with a mock or scramble transfection. Cells treated
with PDK-1 RNAi and exposed to hypoxia demonstrated a
significant (Po0.05) reduction in excreted lactate compared to
scramble-transfected cells in hypoxia at 16, 24 and 48h
(Figure 4A).
Considering pyruvate production, there was no significant
increase after exposure to hypoxia compared to normoxia at any
time point. At 16h, treatment with PDK-1 RNAi compared with
scramble transfection significantly reduced the pyruvate levels in
cells exposed to hypoxia. Overall, there was a gradual reduction in
excreted pyruvate over time in all experimental conditions
(Figure 4B).
Expression of PDK-1 in HNSCC and normal tissues
To investigate potential clinical relevance, the expression of PDK-1
was assessed in normal and malignant head and neck tissues
(Figure 5A–F). The normal tongue or buccal mucosa and
submucosa did not express PDK-1. Strong nuclear expression
was noted in the laryngeal cartilage and strong cytoplasmic
expression in muscular cells. Lymphoid tissue in the tonsils was
negative or weakly positive.
PDK-1 was expressed in all cancer cases examined. The staining
was mainly cytoplasmic, although nuclear expression (in more
than 10% of cancer cells) was noted in 15 of 140 cases. The
percentage of cells with strong cytoplasmic expression ranged
from 0–100% (median 70%). Using the 70% as a cutoff point,
cases were grouped in two categories of low vs high PDK-1
reactivity. Cases with nuclear expression were grouped in the high
reactivity category regardless of the cytoplasmic expression.
Out of 140 cases 81 were considered to bear high PDK-1 reactivity.
PDH expression on the same sections had a similar distribution to
PDK-1.
PDH was expressed in the cytoplasm of tumour cells. In general
well differentiated tumour cells showed stronger immunoreactivity
than less-differentiated cells. A similar proportion of cancer cells
expressed positive immunoreactivity (71–100%). There was no
nuclear expression of PDH in contrast to PDK-1. Considering
the expression characteristics in non-tumour cells, PDH was
expressed in macrophages, vascular endothelial cells, ductal cells
of minor salivary glands, and smooth and striated muscle cells
(Figure 5A–F).
Using the Spearman’s rank correlation for the percentage of
tumour cells with positive immunoreactivity, there was a positive
correlation between tumours expressing PDK-1 and PDH (r¼0.57,
P¼0.03). However, there was no correlation between PDK-1 and
CA-9 expression (r¼0.1, P¼0.72) or between PDH and CA-9
expression (r¼0.21, P¼47).
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Figure 4 Lactate and Pyruvate assays for metabolites in the conditioned
medium of TR-138 cells treated with Scramble (scr) and PDK-1 RNAi.
Assayed at 16, 24 and 48h exposure to 21% oxygen and 0.1% hypoxia for
16h. (A) Lactate and (B) Pyruvate (mmol/100000cells). (C) lactate/
pyruvate ratio. *Po0.05. Results of triplicates, representative of three
experiments.
PDK-1 regulates lactate production in hypoxia
SM Wigfield et al
1980
British Journal of Cancer (2008) 98(12), 1975–1984 & 2008 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s140 120 100 80 60 40 20 0
140 120 100 80 60 40 20 0
Months
Months
0
20
40
60
80
100
D
i
s
e
a
s
e
-
s
p
e
c
i
f
i
c
 
s
u
r
v
i
v
a
l
0
20
40
60
80
100
D
i
s
e
a
s
e
-
f
r
e
e
 
s
u
r
v
i
v
a
l
P=0.005
PDHK1low (59 pts)
PDHK1high (81 pts)
PDHK1low (59 pts)
PDHK1high (81 pts)
P=0.0007
AD
BE
CF
G
Figure 5 Immunohistochemical expression of PDK-1 (A–C) and PDH (D–F). (A) PDK-1 expression surrounding necrosis (*). Inset nuclear expression
(arrow). (B) PDK-1 expression in vascular endothelium (large arrow). (C) PDK-1 expression in skeletal muscle (small arrow). (D) PDH expression in well-
differentiated tumour cells. (E) PDH expression in vascular endothelium (large arrow). (F) PDH expression in skeletal muscle (small arrow). (G) Correlation
with PDK-1 expression and disease-free survival and disease-specific survival.
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sAssociation with histological variables
A marginal association of PDK-1 expression with advanced (T3, 4)
local stage was noted (P¼0.08; Table 2). No association with sex,
age, primary location, node involvement, or histological grade was
noted.
Association with prognosis
Out of 81 cases with high PDK-1 expression, 42 (51.8%). relapsed
locally or at distant sites vs 18 of 59 (30.5%) cases with low PDK-1
expression (P¼0.01) (Figure 5G). Kaplan–Meier disease-free (a)
and disease-specific (b) survival curves showed a significant
poorer prognosis of patients with high PDK-1 expression
(P¼0.0007 and P¼0.005, respectively). The 5-year survival in
these cases was 46.4 vs 70% of patients with low PDK-1 expression.
In multivariate analysis of disease-related death events including
T-stage, N-stage and histological grade, PDK-1 expression was the
only significant and independent prognostic variable (P¼0.009,
t-ratio¼2.64).
DISCUSSION
Hypoxia, through the transcription factor HIF-1, is responsible for
the upregulation of many enzymes involved in glycolysis. Here, we
describe the identification of PDK-1 as a HIF-1 target protein in
HNSCC using a cDNA microarray in SCC-25 cells and show that
PDK-1 not only has an effect on pyruvate and lactate metabolism
but also that it is associated with a significant poor prognosis in
patients with high PDK-1 expression.
Both Q-PCR and western blotting confirmed that PDK-1 was
highly upregulated in hypoxia and, furthermore, its expression was
significantly reduced following treatment with RNAi against
HIF-1a but not HIF-2a, thereby confirming PDK-1 as a HIF-1-
dependent target, which is in agreement with the work by Kim et al
(2006), and Papandreou et al (2006). Several cancer cell lines from
common types of cancer were analysed and they showed that PDK-
1 expression was increased in hypoxia at both the mRNA and
protein level in the majority. These findings suggest that PDK-1 is
not tissue- or tumour-specific, in spite of its selective expression in
a few normal tissues.
To investigate the function of PDK-1, we used gene silencing
using RNAi. Because of the problems with assaying PDH enzyme
activity in crude extracts (Korotchkina et al, 2006), we analysed the
function and activity of PDK-1 using the MTS assay. Although this
is not a specific assay for PDH, previous studies have shown the
utility of analysing the metabolic effects of adding glucose and
pyruvate (Segu et al, 1998) and also shown that it is mainly the
extra mitochondrial enzymes that are measured (Berridge and Tan,
1993). The striking effects in intact cells show the extent of
suppression in cancer cells even under basal conditions. Although
this assay measures a pool of dehydrogenase activity it is the first
demonstration of a change in the activity of the direct target of
PDK-1 in vivo, as opposed to indirect measures of free radical
production or oxygen consumption, which are much smaller.
Although hypoxia reduced the growth of cells, there was no
effect of PDK-1 activity on cell growth. These conditions represent
chronic hypoxia that can occur in tumours. If this reached the
extent of anoxia, we reasoned that on recovery there would be
reoxygenation and that a burst of free radicals from mitochondria
and PDK-1 may protect from that. Under anoxic conditions, there
was no difference in the growth of cells treated with PDK-1 RNAi
compared with control-treated cells. Under anoxic conditions,
there is no mitochondrial respiration, so a difference in growth
rate would not be expected. However, we did observe a small
increase in growth rate after 48h reoxygenation in cells treated
with PDK-1 RNAi. Thus, PDK-1 suppression may allow cells to
produce more ATP per molecule of glucose utilised, increased fatty
acid synthesis and quicker balance of the cells, redox state and
NAD cycle.
We did not see the growth inhibitory effects reported by Kim
et al (2006) or Papandreou et al (2006). This may reflect
differences in cell types, for example, lymphoid cells studied by
Kim et al (2006), and the use of hypoxic-activated toxins in
Papandreou et al (2006).
The excreted lactate and pyruvate were measured during cell
growth in normoxia and hypoxia. This revealed an effect of PDK-1
suppression. After 16h hypoxia, there was a significant increase in
lactate and pyruvate concentrations, which were reduced in the
cells treated with PDK-1 RNAi.
The level of pyruvate at 16h was reduced to levels seen in
normoxia by silencing PDK-1, indicating that PDK-1 isoform is the
principal regulator of the PDH complex in these cells. Importantly,
in this study, it was found that with PDK-1 RNAi treatment, after
48h of exposure to hypoxia, the lactate could be reduced to the
level seen in normoxia. This would suggest that the prolonged
upregulation of PDK-1 in response to hypoxia and HIF-1a is a key
factor in maintaining the elevated lactate and lactate to pyruvate
ratio. The additional information in our study of the application of
this work to clinical tumour samples showed a major prognostic
difference in those tumours with PDK-1 expression. PDK-1 is
highly expressed in cardiac, brain, lung, and kidney tissue, but
clearly it was differentially expressed in malignant tissues. The
expression pattern seen was predominantly cytoplasmic, which is
Table 2 Association of PDK-1 expression with local stage, sex, age,
primary location, node involvement or histological grade
PDK-1
No of cases Low High P-value
Gender
F 42 20 22 0.45
M9 8 3 9 5 9
Age
o60 71 33 38 0.30
460 69 26 43
Region
Hypopharynx 17 6 11
Larynx 28 15 13 0.55
Oropharynx 46 19 27
Oral cavity 49 19 30
T-stage
T1 25 15 10
T2 33 14 19 0.08(*)
T3 28 10 18
T4 54 20 34
N-stage
04 9 2 0 2 9
1 31 12 19 0.81
25 4 2 5 2 9
36 2 4
UICC-stage
11 0 4 6
2 19 9 10 0.35
33 1 1 5 1 6
4a 80 31 49
Differentiation
Good 16 7 9
Moderate 58 23 35 0.68
Poor 66 29 37
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lung cancer (Giatromanolaki et al, 2001; Koukourakis et al, 2005b).
Not previously reported was the finding that PDK-1 demonstrated
nuclear expression in a subset of cancers. Although the function of
this nuclear fraction is unknown, other glycolytic enzymes have
also been reported to show nuclear expression. A high proportion
of HNSCC tumours expressed high levels of both PDK-1 and PDH.
This is in contrast to a previous study that reported PDH is
decreased in epidermal tumours compared to normal epidermis
(Eboli and Pasquini, 1994).
The striking and adverse outcome of those tumours with highest
PDK-1 expression could be related to a survival benefit on the
cancer cells in vivo, perhaps indicating that marginal hypoxic/
anoxic cells are important for tumour growth. We have previously
measured HIF-1a and HIF-2a, as well as carbonic anhydrase 9, the
erythropoietin receptor and erythropoietin, and EGF receptor in
this series of cases (Winter et al, 2005, 2006). None of those
markers was as strong a factor in predicting outcome as PDK-1.
This may indicate the relative importance of one pathway induced
by hypoxia vs another one. We recently carried out a gene array
analysis of a series of primary head and neck cancers and showed
that the hypoxia gene profile differs in every case (Kong et al,
2006). Therefore, it is possible that some pathways are biologically
more important than others and hence predict outcome better.
Another possibility is that it is a robust marker of HIF-1a
signalling, not specifically related to its function, the former being
shown by several groups to be associated with poor outcome in
this and other cancer types. Also, the antigen may be better
preserved than HIF and thus more reliable.
We propose a mechanism based on our observation that PDK-1
activity maintains lactate levels in the extracellular medium at
about 2-fold higher, most likely by preventing pyruvate metabo-
lism and its entry into the mitochondrial pathway. The high
activity of LDHA and monocarboxylate transporters also increased
in hypoxia through HIF-1, combined with the inability of cells to
convert pyruvate to acetyl CoA by activating PDK-1 results in
elevated lactate (Brahimi-Horn et al, 2007). Lactate can enhance
and maintain HIF activation through inhibition of prolyl hydro-
xylases (Lu et al, 2005). This would have the effect of amplifying
the Warburg effect and, indeed, a role of PDK-1 may be to
contribute to the effect.
High levels of lactate have been associated with a poor outcome
in a number of tumours, including HNSCC (Walenta et al,
1997; Brizel et al, 2001). However, additionally, LDHA has
recently been shown to have a critical role in the energy
production of cancer cells through glycolysis, and maintaining
this pathway may be a more important aspect of inhibition of
PDH (Fantin et al, 2006). Recently, Cairns et al (2007) have
demonstrated that the mitochondrial metabolism of tumour
cells is increased by the pharmacologic inhibition of PDK-1. The
acute increase in oxygen consumption leads to a corresponding
decrease in tumour oxygenation, thereby increasing the
effectiveness of some traditional therapies. It will, therefore,
be of interest to investigate the relevance of the PDK-1 pathway
in in vivo models to determine whether inhibitors will be
worthwhile to develop clinically and also the relative importance
of enhancement of lactate production vs suppression of mitochon-
drial function.
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